# Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use

> **NCT01223456** · — · TERMINATED · sponsor: **AstraZeneca** · enrollment: 542 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01223456
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 542 (ACTUAL)
- **Why stopped:** Inability to recruit adequate number of patients within the specified time period.
- **Last updated:** 2013-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01223456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01223456, "Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01223456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*